Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Genes, Chromosomes & Cancer|April 19, 2017
A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemiaNadine Sandhöfer, Klaus H Metzeler, Purvi M Kakadia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusionsRitu Salani, Ben Davidson, Michael Fiegl, et al.
Blood|November 19, 2005
Identification of glucocorticoid-response genes in children with acute lymphoblastic leukemiaStefan Schmidt, Johannes Rainer, Stefan Riml, et al.
Plos One|May 29, 2015
Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study)Wolfgang Hilbe, Georg Pall, Florian Kocher, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|August 13, 2014
Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironmentJuliana Velez, Leonardo José Enciso, Marta Suarez, et al.
Blood|December 5, 2013
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330Christina Krupka, Peter Kufer, Roman Kischel, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2015
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registryFlorian Kocher, Wolfgang Hilbe, Andreas Seeber, et al.
Haematologica|May 13, 2014
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapseMax Hubmann, Thomas Köhnke, Eva Hoster, et al.
Blood|January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCGJan Braess, Karsten Spiekermann, Peter Staib, et al.
Blood|June 12, 2016
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemiaKlaus H Metzeler, Tobias Herold, Maja Rothenberg-Thurley, et al.
Pageof 11